Company Description With over 25 years’ experience, plus the same enormous passion and ambition we had on day-one, we’re trailblazers in the pet e-commerce industry. Our solutions make over 12 million customers genuinely happier – and
Snap Inc is a technology company. We believe the camera presents the greatest opportunity to improve the way people live and communicate. Snap contributes to human progress by empowering people to express themselves, live in the
We at Yara are part of a global network, collaborating to profitably and responsibly solve some of the worlds key challenges - resource scarcity, food insecurity and environmental change. About the Unit YARA Environmental Technologies is
Requisition ID: 7565 Grade: G3 Country: Austria Duty Station: Vienna Category: General Service/Admin. Support Type of Job Posting: Internal and External Employment Type: Staff-Full-time Appointment Type: Fixed Term - 100 series Indicative Minimum Net Annual Salary:
Description WORK LOCATION: Vienna, Austria PROJECT DURATION: 36 MONTHS WITH EXPECTED FOLLOW-ON WORK WITHIN THE DoS PROGRAM Drafting and producing full gamut of construction project controls report (MS Office Suite), cost management, schedule management (Primavera), change
Description WORK LOCATION: Vienna, Austria (U.S. Embassy) PROJECT DURATION: 36 MONTHS WITH EXPECTED FOLLOW-ON WORK WITHIN THE DoS PROGRAM The Engineer is responsible for performing technical inspections of electrical work, monitoring the contractors quality control program,
Software Engineer Angular / Java with experience (m/f/d) Your code could save lives! Software development is your passion and you are eager to apply state-of-the-art technology in the medical domain? Then this is the right place for
Who we are We simplify wealth creation. Founded in 2014 in Vienna, Austria by Eric Demuth, Paul Klanschek and Christian Trummer, we’re here to help people trust themselves enough to build their financial freedom — for
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)